Antioxidant micronutrients for lung disease in cystic fibrosis
Información
- DOI:
- https://doi.org/10.1002/14651858.CD007020.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 08 diciembre 2010see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Fibrosis quística y enfermedades genéticas
- Copyright:
-
- Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
SV is the guarantor of this review.
LS and SV conceived this review and secured funding for it.
LS and NB performed previous work that was the foundation of the current review.
LS lead the design and ongoing coordination of this review with oversight from SV.
SV, DA, JJ and NB provided general guidance and a methodological perspective on this review on an ongoing basis.
LS developed the additional search strategies and carried out the searches for this review including "grey literature" (i.e. literature which is not easily accessible through electronic databases).
LS organized retrieval of papers for this review.
LS and DA screened retrieved papers against inclusion criteria for this review.
SV settled disagreements between LS and DA regarding included studies for this review.
LS and DA independently appraised the quality of papers for this review.
LS and DA independently abstracted data from papers for this review.
LS wrote to authors of included studies for additional information for this review.
LS managed data for the review including entering data into RevMan and analyzing the data with the assistance of a statistician if needed.
LS and SV interpreted data for this review.
LS wrote the review with revisions suggested by NB, JJ, SV.
Sources of support
Internal sources
-
Department of Pediatrics Trainee Grant, University of Alberta, Canada.
-
Alberta Heritage Foundation for Medical Research (AHFMR), Canada.
SV and DA receive salary support from the Alberta Heritage Foundation for Medical Research (AHFMR).
-
Canadian Institutes of Health Research, Canada.
SV receives salary support from the Canadian Institutes of Health Research
-
SickKids Foundation, Canada.
LS receives salary support from the SickKids Foundation
External sources
-
No sources of support supplied
Declarations of interest
None identified.
Acknowledgements
The authors would like to thank Leah Vanderjagt for her contribution to the search strategy, Ben Vandermeer for his assistance with the statistical analysis and Margaret Sampson for her guidance and input at various stages of the review process.
Version history
| Published | Title | Stage | Authors | Version |
| 2019 Oct 03 | Antioxidant supplementation for lung disease in cystic fibrosis | Review | Oana Ciofu, Sherie Smith, Jens Lykkesfeldt | |
| 2014 Aug 07 | Antioxidant supplementation for lung disease in cystic fibrosis | Review | Oana Ciofu, Jens Lykkesfeldt | |
| 2010 Dec 08 | Antioxidant micronutrients for lung disease in cystic fibrosis | Review | Larissa Shamseer, Denise Adams, Neil Brown, Jeffrey A Johnson, Sunita Vohra | |
| 2008 Apr 23 | Antioxidant micronutrients for lung disease in cystic fibrosis | Protocol | Larissa Shamseer, Denise Adams, Neil Brown, Jeffrey A Johnson, Sunita Vohra | |
Differences between protocol and review
Each antioxidant micronutrient or unique combination of micronutrients were analysed as separate subgroups within meta‐analyses since their mechanisms of action are different.
Quality assessment was conducted using Cochrane's newly adopted risk of bias (RoB) tool rather than the Jadad scale and as such proposed sensitivity analyses were to be based on RoB assessments.
Sensitivity analysis was intended for all outcomes, rather than just lung function, oxidative stress and inflammatory stress outcomes as stated in the protocol.
Three secondary outcomes were revised after the review process began. Categories of oxidative stress outcomes were revised and pulmonary exacerbations were not specifically collected since this data appeared in the literature as "days of antibiotic therapy".
After statistical advice from the statistical peer reviewer and the CFGD Group's statistical editor, we now plan to present results for adverse events using Peto OR rather than the risk difference.
